Overexpression of epithelial cell adhesion molecule (EpCAM) in gastric cancer and its correlation with overall survival of the patients

Authors

  • Mehdi Mohammadi Cancer and Immunology Research Center, Kurdistan University of Medical Science, Sanandaj, Iran https://orcid.org/0000-0002-2103-6913
  • Ali Jalili Cancer and Immunology Research Center AND Liver and Digestive Research Center, Kurdistan University of Medical Science, Sanandaj, Iran
  • Bahram Nikkhoo Cancer and Immunology Research Center, Kurdistan University of Medical Science, Sanandaj, Iran
  • Daem Roshani Cancer and Immunology Research Center, Kurdistan University of Medical Science, Sanandaj, Iran
  • Kaveh Tari Cancer and Immunology Research Center, Kurdistan University of Medical Science, Sanandaj, Iran
  • Farshad Sheikhesmaili Liver and Digestive Research Center, Kurdistan University of Medical Science, Sanandaj, Iran http://orcid.org/0000-0002-4439-123X

DOI:

https://doi.org/10.22122/cdj.v7i1.374

Keywords:

Epithelial Cell Adhesion Molecule, Gastric Cancer, Tumors

Abstract

BACKGROUND: Epithelial cell adhesion molecule (EpCAM) is an adhesion molecule which is expressed on the epithelial cells and primarily identified as a tumor marker for carcinoma. In this study, the expression of EpCAM in precancerous and cancerous gastric lesions was investigated and then, the association of EpCAM expression with the overall survival of patient suffering from gastric carcinoma was evaluated.

METHODS: 12 gastric carcinoma, 3 dysplasia, and 8 intestinal metaplasia (IM) subjects were taken from the department of pathology of Tohid Hospital, Sanandaj, Iran. The diagnosis was made by the expert pathologist. Then, the subjects were stained for EpCAM by immunohistochemistry (IHC) and analyzed by the pathologist.

RESULTS: The data showed that EpCAM was expressed in all of the precancerous and cancerous samples. However, 76.4% of carcinoma cells were positive for EpCAM while it was 62.5% and 51.3% for dysplasia and IM, respectively. Importantly, it was observed that the expression of EpCAM on gastric cancer was negatively correlated with the overall survival of the patients.

CONCLUSION: In conclusion, it was demonstrated in this study that EpCAM is expressed in gastric carcinoma and its expression is negatively correlated with the overall survival of the patients with gastric cancer.

References

Wenqi D, Li W, Shanshan C, Bei C, Yafei Z, Feihu B, et al. EpCAM is overexpressed in gastric cancer and its downregulation suppresses proliferation of gastric cancer. J Cancer Res Clin Oncol 2009; 135(9): 1277-85.

Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: Review and considerations for future directions. Ann Surg 2005; 241(1): 27-39.

Takahashi T, Saikawa Y, Kitagawa Y. Gastric cancer: Current status of diagnosis and treatment. Cancers (Basel ) 2013; 5(1): 48-63.

Nagini S. Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol 2012; 4(7): 156-69.

Kroepil F, Dulian A, Vallbohmer D, Geddert H, Krieg A, Vay C, et al. High EpCAM expression is linked to proliferation and lauren classification in gastric cancer. BMC Res Notes 2013; 6: 253.

Du W, Ji H, Cao S, Wang L, Bai F, Liu J, et al. EpCAM: A potential antimetastatic target for gastric cancer. Dig Dis Sci 2010; 55(8): 2165-71.

Patriarca C, Macchi RM, Marschner AK, Mellstedt H. Epithelial cell adhesion molecule expression (CD326) in cancer: A short review. Cancer Treat Rev 2012; 38(1): 68-75.

Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U, et al. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 2006; 94(1): 128-35.

Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17-1A antigen (Ep-CAM). J Mol Med (Berl) 1999; 77(10): 699-712.

Liu JJ, Lichtensztajn DY, Gomez SL, Sieh W, Chung BI, Cheng I, et al. Nationwide prevalence of lymph node metastases in Gleason score 3 + 3 = 6 prostate cancer. Pathology 2014; 46(4): 306-10.

Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol 2004; 35(1): 122-8.

Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC. Epithelial cell adhesion molecule: More than a carcinoma marker and adhesion molecule. Am J Pathol 2007; 171(2): 386-95.

Joo M, Kim H, Kim MK, Yu HJ, Kim JP. Expression of Ep-CAM in intestinal metaplasia, gastric epithelial dysplasia and gastric adenocarcinoma. J Gastroenterol Hepatol 2005; 20(7): 1039-45.

Mukherjee S, Richardson AM, Rodriguez-Canales J, Ylaya K, Erickson HS, Player A, et al. Identification of EpCAM as a molecular target of prostate cancer stroma. Am J Pathol 2009; 175(6): 2277-87.

Yanamoto S, Kawasaki G, Yoshitomi I, Iwamoto T, Hirata K, Mizuno A. Clinicopathologic significance of EpCAM expression in squamous cell carcinoma of the tongue and its possibility as a potential target for tongue cancer gene therapy. Oral Oncol 2007; 43(9): 869-77.

Pak MG, Shin DH, Lee CH, Lee MK. Significance of EpCAM and TROP2 expression in non-small cell lung cancer. World J Surg Oncol 2012; 10: 53.

Downloads

Published

2019-01-17

How to Cite

1.
Mohammadi M, Jalili A, Nikkhoo B, Roshani D, Tari K, Sheikhesmaili F. Overexpression of epithelial cell adhesion molecule (EpCAM) in gastric cancer and its correlation with overall survival of the patients. Chron Dis J. 2019;7(1):49–52.

Issue

Vol 7, No 1 (2019)

Section

Original Article(s)

Most read articles by the same author(s)